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Abstract
Monocytic lineage cells (monocytes, macrophages and dendritic cells) play important roles in immune responses and are
involved in various pathological conditions. The development of monocytic cells from human embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs) is of particular interest because it provides an unlimited cell source for clinical
application and basic research on disease pathology. Although the methods for monocytic cell differentiation from ESCs/
iPSCs using embryonic body or feeder co-culture systems have already been established, these methods depend on the use
of xenogeneic materials and, therefore, have a relatively poor-reproducibility. Here, we established a robust and highly-
efficient method to differentiate functional monocytic cells from ESCs/iPSCs under serum- and feeder cell-free conditions.
This method produced 1.3610660.36106 floating monocytes from approximately 30 clusters of ESCs/iPSCs 5–6 times per
course of differentiation. Such monocytes could be differentiated into functional macrophages and dendritic cells. This
method should be useful for regenerative medicine, disease-specific iPSC studies and drug discovery.
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Introduction
Monocytic lineage cells, such as monocytes, macrophages and
dendritic cells (DCs), are central to immune responses and play key
roles in various pathological conditions. [1–2] Monocytes are the
myeloid progeny of hematopoietic stem/progenitor cells [3]; they
are a type of mononuclear cell circulating in the bloodstream and
act as gatekeepers in innate immunity. While they replenish
macrophages and DCs, monocytes themselves respond to various
inflammatory stimuli by migrating into inflamed tissues, phago-
cytosing pathological small particles and producing proinflamma-
tory cytokines and chemokines. Therefore, monocytes not only
contribute to host defense against pathogenic microorganisms, but
are closely associated with the pathogenesis of chronic sterile
inflammation. [4] Macrophages reside in tissues and robustly
phagocytose microorganisms and cellular debris. One of the
important hallmarks of monocytic lineage cells is their functional
plasticity. In response to cytokines and microbial products,
macrophages polarize into functionally distinct M1 and M2 cells.
[5] Classically activated M1 macrophages are induced by in-
terferon-c (IFNc), while alternatively activated M2 macrophages
can be induced by IL-4 and IL-13. [2,5] M1 macrophages are
generally characterized by high production of proinflammatory
cytokines, while M2 are characterized by high production of anti-
inflammatory cytokines. DCs are the most powerful antigen-
presenting cells and have an indispensable role for the activation of
T lymphocytes. Because of their ability to mediate communication
between innate and acquired immunity, ex vivo expansion of DCs
is expected to be a useful source of material for cancer
immunotherapies, such as DC-based vaccines. [6–7] Moreover,
recent reports of monocyte and/or DC deficiencies highlight the
importance of understanding their development in humans. [8]
However, there have been technical limitations for tracing the
development of human monocytic cells, or for propagating them
ex vivo.
Human embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) are undifferentiated pluripotent cells that can be
propagated indefinitely. [9–11] The development of monocytic
cells from these pluripotent cells is of particular interest because it
would provide an unlimited source of these cells for clinical
applications and the examination of disease pathologies. Although
the methods for hematopoietic differentiation from ESCs/iPSCs
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using embryonic body or feeder co-culture systems have already
been established, [12] these methods usually depend on xenoge-
neic feeder cells and/or animal- or human-derived serum, and
therefore have a relatively poor-reproducibility. For instance,
batch-to-batch variability of serum or feeder cells can influence the
characteristics of in vitro differentiated DCs. [13] Here, we describe
a novel serum- and feeder cell-free method that robustly and




This study used human ESCs (cell line: KhES1) and iPSCs (cell
lines: 201B7, 253G4, CIRA188Ai-W2, and CB-A11). [10,14–15]
201B7, 253G4 [10] and CIRA188Ai-W2 [15] were previously
described. A human ES cell line KhES1 was kindly provided by
Dr. Norio Nakatsuji. Human iPS cell lines 201B7 and 253G4 were
kindly provided by Dr. Shinya Yamanaka. CB-A11 was
established from cord-blood mononuclear cells by using episomal
vectors. [16] These ESCs/iPSCs were maintained on tissue culture
dishes coated with growth factor-reduced Matrigel (Becton-
Dickinson) in mTeSR1 serum-free medium (STEMCELL Tech-
nologies).
Monocytic Lineage Cell Differentiation Method
The monocytic lineage differentiation protocol was modified
from a previously established hematopoietic differentiation pro-
tocol (Figure 1). [17] The protocol consists of 5 sequential steps by
which mature MPs and DCs are differentiated from human
pluripotent cells in a stepwise manner. In the first step, primitive
streak cells were induced from undifferentiated ESCs/iPSCs,
which were then differentiated into hemangioblast-like hemato-
poietic progenitors in the second step. In step 3, expanded
hematopoietic progenitors were committed towards initial myeloid
differentiation, and then differentiated into the monocytic lineage
in step 4. Finally, CD14+ monocytes were differentiated into either
MPs or DCs in step 5. The cytokines used in this study were
purchased from R&D systems.
Step 1: induction of primitive streak-like cells from
undifferentiated human ES/iPS cells with BMP4. BMP4
is an important molecule for the initial stage of mesodermal
commitment of pluripotent stem cells in vitro. [17] Undifferenti-
ated ESCs/iPSCs colonies were disseminated onto a 100 mm
culture dish coated with growth factor-reduced Matrigel in
mTeSR1 medium at a density of about 30 colonies per dish.
Individual colonies were grown to a diameter of approximately
1 mm (Day 0), and BMP4 (80 ng/mL) was added to the mTeSR1
medium.
Step 2: generation of KDR+CD34+ hemangioblast-like
cells with VEGF, basic FGF and SCF. VEGF and SCF have
been reported to be important cytokines for development of
hemoangiogenic progenitors. [18–19] In this step, we also added
basic FGF which enhances the development of mesodermal
hematopoietic progenitors. [18,20] The mTeSR1 medium was
replaced by StemPro-34 serum-free medium (Gibco) containing
2 mM glutamax (Invitrogen) on day 4, and then was supplemen-
ted with the step-2 cytokine cocktail composed of VEGF (80 ng/
mL), basic FGF (25 ng/ml), and SCF (100 ng/mL).
Figure 1. Protocol for monocytic lineage cell differentiation from human pluripotent stem cells. The protocol is composed of 5 steps.
CD14-positive cells that are sorted between step-4 are differentiated into dendritic cells by step 5-1 or into macrophages by step 5-2. FL-3: Flt-3
ligand, TPO: Thrombopoietin.
doi:10.1371/journal.pone.0059243.g001
Human ES/iPSC-Derived Functional Monocytic Cells
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e59243
Figure 2. Phenotype analysis and gene expression pattern of monocytic lineage cells derived from pluripotent stem cells. (A) Flow
cytometric analysis of monocytic lineage cells derived sequentially from pluripotent stem cells. An analysis of adherent cells on day 6 and supernatant
cells on day 13 and 18 is shown. (B) May-Giemsa staining of CD14+ monocyte-like cells derived from KhES1 on day 16 (left) and primary human
monocytes (right). (C) Esterase staining for CD14+ monocyte-like cells derived from KhES1 on day 16. (D) The percentage of CD14+ cells within the
total floating cells derived from KhES1/iPS-201B7 was evaluated from day 13 to day 28. (E) May-Giemsa staining (left) and phase contrast image (right)
Human ES/iPSC-Derived Functional Monocytic Cells
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Step 3: generation of hematopoietic cells with
hematopoietic cytokines. The cytokines in StemPro-34 me-
dium were switched to the step-3 cytokine cocktail composed of
SCF (50 ng/mL), IL-3 (50 ng/mL), TPO (Thrombopoietin)
(5 ng/mL), M-CSF (50 ng/mL), and Flt-3 ligand (50 ng/mL),
on day 6. Thereafter, the medium was changed on day 10.
Step 4: monocytic lineage-directed differentiation with
Flt-3 ligand, GM-CSF and M-CSF. The cytokines in StemPro-
34 medium were switched to the step-4 cytokine cocktail
composed of Flt-3 ligand (50 ng/mL), GM-CSF (25 ng/mL),
and M-CSF (50 ng/mL) on day 13–15. The medium was changed
every 3–4 days. The CD14+ monocytic lineage-directed cell
fraction in supernatant was positively sorted by autoMACS pro
(Miltenyi Biotec) with CD14 MicroBeads (Miltenyi Biotec) on days
15–28.
Step 5: differentiation into DCs (step 5-1) and MPs (step
5-2) from CD14+monocytic lineage-cells. CD14+ cells sorted
by autoMACS pro (1.56106 cells per well in a 6-well plate with
Ultra-Low Attachment Surface (CORNING)) were cultured in
StemPro-34 medium supplemented with GM-CSF (25 ng/mL)
and IL-4 (40 ng/mL), with a medium change 4 days later, for
differentiation into DCs (step 5-1). LPS (100 ng/mL, InvivoGen)
and TNFa (0.2 ng/mL) were added for the last 2 days of the 7 day
DC differentiation culture to promote maturation of DCs. CD14+
cells (1.56106 cells per well in a 6-well tissue culture plate) were
cultured in RPMI-1640 medium (Sigma) supplemented with 10%
of mature DCs derived from pluripotent stem cells. (F) Flow cytometric analysis of immature/mature DCs derived from pluripotent stem cells. (G)
Phase contrast image and flow cytometric analysis of macrophages derived from pluripotent stem cells.(H) RT-PCR analysis of monocytic lineage cells
derived from KhES1/iPS-201B7 clones for expression of monocytic lineage marker genes (PU.1, c-MAF, TLR4, CCL17 and CCL18). Peripheral blood
monocytes and peripheral blood monocyte-derived mature DCs were used as positive controls.(A–C, E–G) The data from KhES1-derived cells are
shown as representative.
doi:10.1371/journal.pone.0059243.g002
Figure 3. Functional assays for monocytes derived from pluripotent stem cells. (A) The levels of IL-6 and TNFa in supernatants of PS-Mo
culture medium 4 hours after LPS stimulation. The levels of IL-1b were measured 4 hours after LPS stimulation with/without an additional 30-minute
ATP stimulation. (B) Flow cytometric analysis of CX3CR1 on PS-Mo. (C) Chemotaxis assay of PS-Mo for CX3CL1 (fractalkine) using a trans-well
migration assay. After the addition of CX3CL1 into either the bottom or top of the trans-well chamber, PS-Mo were applied and incubated for 5 hours
at 37uC. (D) Antigen uptake was evaluated in monocytes, immature DCs and mature DCs derived from pluripotent stem cells by examining the
fluorescence intensity of Alexa fluor 488-conjugated ovalbumin 45 minute after incubation at 37uC (black). Control samples (white) were kept on ice.
(B–D) The data of KhES1-derived cells are shown as representative. PS-Mo: monocyte derived from pluripotent stem cells.
doi:10.1371/journal.pone.0059243.g003
Human ES/iPSC-Derived Functional Monocytic Cells
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fetal bovine serum (FBS) and M-CSF (100 ng/mL) for 7 days with
a medium change at day 4, for differentiation into macrophages
(step 5-2). IFNc (20 ng/ml) or IL-4 (20 ng/ml) was added for
another day to promote differentiation into M1 or M2 macro-
phages, respectively.
Flow Cytometric Analysis
Flow cytometric analysis data were collected using the MACS
QuantTM Analyzer (Miltenyi Biotec) and then analyzed utilizing
the FlowJo software package (Treestar). The following antibodies
were purchased from BD Biosciences: CD11b-FITC, CD11c-
APC, CD34-PE, CD40-PE, CD43-FITC, CD80-PE, CD83-PE,
CD86-FITC, CD205-Alexa fluor 647, CD206-FITC, CD209-PE,
HLA-ABC-FITC and HLA-DR-FITC. CD14-APC and CD45-
APC antibodies were purchased from Beckman Coulter. CD163-
APC antibody was purchased from R&D systems. KDR (CD309)-
Alexa fluor 647 and CX3CR1-PE antibodies were purchased from
Biolegend.
May-Giemsa Staining and Esterase Staining
Cells were seeded onto glass slides by CYTOSPIN 4 (Thermo
Scientific) and stained with May-Grunwald and Giemsa staining
solution (MERCK) and Esterase staining solution (Muto pure
chemicals) following the manufacturer’s instructions.
RNA Extraction and RT-PCR Analysis
RNA samples were prepared using the RNeasy mini kit
(Qiagen) following the manufacturer’s instructions. Typically,
500 ng of total RNA were subjected to reverse transcription
(RT) with a Sensiscript-RT kit (Qiagen). RT-PCR was performed
for the evaluation of the expression of monocytic lineage marker
genes such as PU.1, MAF, TLR4, CCL17 and CCL18 using the
primers in Table S1. [21–22] Peripheral blood monocyte-derived
mature DCs/macrophages were generated from peripheral
CD14+ monocytes using the step 5-1/5-2 cytokine cocktails in
10% FBS-supplemented RPMI-1640 for use as positive controls.
Cytokine Assay
Concentrations of cytokines (IL-1b, IL-6, IL-10, IL-12p70 and
TNFa) in supernatants were analyzed with FlowCytomix kits
(Bender MedSystems) following the manufacturer’s instructions.
The IL-1b, IL-6 and TNFa levels in the culture supernatants of
pluripotent cell-derived monocytes (PS-Mo) were analyzed in three
settings, (1) culture in RPMI-1640 medium supplemented with
10% FBS and LPS (100 ng/ml) for 4.5 hours, (2) as in (1) but with
Figure 4. Functional assays for dendritic cells derived from pluripotent stem cells. (A) Flow cytometric analysis of immature/mature DCs
derived from pluripotent stem cells. (B) The levels of IL-10 and TNFa in supernatants of culture medium with PS-DCs 24 hours after LPS stimulation.
(C) The proliferation of allogeneic naı¨ve T cells (16105 cells per well) co-cultured with 40 Gy-irradiated stimulator cells for 3 days was evaluated. The
proliferation of naı¨ve T cells in the last 16 hours was measured by 3H-thymidine uptake. (A–C) The data of KhES1-derived cells are shown as
representative.
doi:10.1371/journal.pone.0059243.g004
Human ES/iPSC-Derived Functional Monocytic Cells
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Figure 5. Functional assays for M1/M2 macrophages derived from pluripotent stem cells. (A) Flow cytometric analysis of M1/M2
macrophages derived from pluripotent stem cells. (B) The levels of IL-12p70 and IL-10 in supernatants of culture medium with M1/M2 macrophages
derived from pluripotent stem cells 24 hours after LPS stimulation. The data of KhES1-derived cells are shown as representative.
doi:10.1371/journal.pone.0059243.g005
Human ES/iPSC-Derived Functional Monocytic Cells
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the addition of ATP (1 mM) for the last 30 min, (3) without LPS or
ATP for 4.5 hours, to evaluate the production pattern of IL-1b in
response to LPS plus ATP. [23].
The levels of IL-6, IL-10, IL-12p70 and TNFa in the
supernatants of M1 or M2 macrophage culture were measured
24 hours after LPS (100 ng/ml) stimulation.
Chemotaxis Assay
PS-Mo chemotaxis was evaluated using a trans-well migration
assay with 8-mm pore size inserts (BD Biosciences). After CX3CL1
(fractalkine; R&D systems) was added to either the bottom or top
of the chamber, serum-starved PS-Mo were loaded onto the inserts
which were placed into 24-well plates containing RPMI-1640 and
then incubated at 37uC for 5 hours. [24] Cell migration was
measured by flow cytometry as previously reported: equivalent
amounts of counting beads were added to each sample and the
ratios of PS-Mo to the counting beads were calculated. [25].
Antigen Uptake Assay
The antigen uptake capacity of monocytic lineage cells was
evaluated as previously described. [26] Briefly, the cells were
collected and stored on ice for 10 min. PS-Mo, pluripotent cell-
derived immature DCs (PS-imDCs) and pluripotent cell-derived
mature DCs (PS-mDCs) (56104 cells) were incubated with
Ovalbumin Alexa fluor 488 Conjugate (Molecular Probes) at
0.1 mg/ml at 37uC or on ice for 45 min. Ice-cold FACS buffer
was added in order to stop the reaction, samples washed twice, and
the fluorescence intensity analyzed by flow cytometry.
Mixed Leukocyte Reactions
Allogeneic naı¨ve T cells (16105 cells per well) were purified
from umbilical cord blood mononuclear cells using naı¨ve CD4+ T
cell isolation kits (Miltenyi Biotec) and then co-cultured with
40 Gy-irradiated stimulator cells (PS-Mo, PS-imDC, and PS-
mDC) in 96-well round bottomed culture plates for 3–5 days. 3H-
methylthymidine (25 uCi/ml, Moravek Biochemicals and Radio-
chemicals) was added to the culture medium of 10% FBS-
supplemented RPMI-1640 for the last 16 hours. The cells were
harvested onto a filter mat (Perkin Elmer) and the 3H
methylthymidine uptake determined using a scintillation counter
(MicroBeta TriLux, Perkin Elmer).
Ethical Considerations
This study was approved by the Ethics Committee of Kyoto
University and written informed consent was obtained from each
healthy volunteer.
Statistics
Data are presented as the mean 6 S.D. and the statistical
significance of the differences between cultures were evaluated by
Student’s t-test.
Results
Differentiation of ESCs/iPSCs into Dendritic Cells and
Macrophages via Monocyte-like Cells
A KDR+CD34+ hemangioblast-like population was detected
in adherent cell clusters on day 6 (steps 1,2), and around 95%
of supernatant cells were CD43+CD45+ hematopoietic cells on
days 13–15 (step 3; Figure 2A). [17] Floating cells were
recovered every 3–4 days in step 4 (Figure S1); the majority of
these cells were CD14+ monocyte-like cells (Figure 2A). These
pluripotent cell-derived monocytes (PS-Mo) were similar to
peripheral blood monocytes in morphology (Figure 2B). PS-
Mo are positive for Esterase staining which was inhibited by
NaF (Figure 2C). The percentages of PS-Mo in floating cells
were constantly about 50–90% between day 18–28 (Figure 2D
and Figure S2A). The yield of PS-Mo per 100 mm culture
dish starting with about 30 colonies was 1.3610660.36106 at
each step-4 medium exchange.
To derive DCs, PS-Mo were purified by magnetic sorting, and
differentiated into CD142CD832 immature DCs (PS-imDCs)
with the step 5-1 cytokine cocktail in 5 days (Figure 2E). PS-
imDCs were stimulated with LPS and TNFa for an additional 2
days, which further differentiated them into CD142CD83+
mature DCs (PS-mDCs) (Figure 2F). The differentiation
efficiency of mature DCs from PS-Mo was comparable to that
from primary monocytes (7.7%60.9% vs. 16.5%61.0%, p = 0.20,
unpaired Student’s t-test). PS-Mo also had the potential to
differentiate into macrophages (PS-MPs) with the step 5-2 cytokine
cocktail. PS-MPs are morphologically comparable to primary
monocyte-derived macrophages and they express typical surface
markers such as CD14 and CD68 (Figure 2G and Figure
S3A,B).
We confirmed that PS-Mo, pluripotent cell-derived DCs (PS-
DCs), and PS-MPs expressed monocytic lineage-specific genes
(Figure 2H and Figure S2B). [22,27] Collectively, by using this
protocol, sufficient numbers of monocytic cell lineage cells can be
obtained from a small number of human ESCs/iPSCs.
Functional Assays for Monocytes Derived from ESCs/
iPSCs
Next, we evaluated the functional activity of pluripotent cell-
derived monocytic lineage cells. PS-Mo robustly produced the pro-
inflammatory cytokines IL-6 and TNFa after LPS stimulation
(Figure 3A, Figure S3C). Secretion pattern of IL-1b from PS-
Mo with two stepwise signals LPS and ATP were similar to
primary monocytes (Figure 3A, Figure S3D). [23,28].
PS-Mo expressed CX3CR1, implying chemotactic responses
to CX3CL1 (fractalkine) (Figure 3B). PS-Mo migration in
trans-well assays increased with increasing doses of CX3CL1 in
the lower compartment of the chamber (Figure 3C). This
phenomenon was not due to chemokinesis, but chemotaxis,
because CX3CL1 in the top compartment could not induce PS-
Mo migration into the lower compartment of the chamber. [24]
We next compared the antigen uptake ability of PS-Mo, PS-
imDCs, and PS-mDCs by incubating them with Ovalbumin
Alexa fluor 488 Conjugate. [26] PS-Mo had the highest ability
to take up antigen and as DCs matured they lost their ability to
endocytose antigens (Figure 3D).
Functional Assays for DCs Derived from ESCs/iPSCs
For evaluating functions of PS-DCs, we first confirmed that
patterns of expression of cell surface markers on PS-imDCs/
mDCs were comparable to those on primary dendritic cells
(Figure 4A, Figure S4A). When stimulated with LPS and TNFa,
PS-DCs also produced almost comparable amounts of pro-
inflammatory and anti-inflammatory cytokines (Figure 4B,
Figure S4B).
To test the ability of PS-DCs to activate naı¨ve T cells, we next
co-cultured allogeneic naı¨ve T cells with PS-DCs and PS-Mo. As
shown in Figure 4C, PS-mDCs had the most potent capacity to
stimulate allogeneic T cell proliferation and this dose-response
relationship was comparable to that observed with PB-DCs (Figure
S4C).
Human ES/iPSC-Derived Functional Monocytic Cells
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e59243
Functional Assays for Macrophages Derived from ESCs/
iPSCs
Using this technique, we obtained morphologically typical
macrophage-like cells that adhered firmly to the culture dish. To
test whether these PS-MPs possessed functional plasticity like
primary macrophages, we tried to polarize them into M1 or M2
state by treating them with IFNc or IL-4, respectively. PS-MPs
exhibited typical surface markers that were characteristic of
primary M1 or M2 macrophages (Figure 5A, Figure S5A). The
M1 cytokine pattern is typically IL-12high and IL-10low, whereas
the M2 pattern is IL-12low and IL-10high. [5] Pluripotent cell-
derived M1 and M2 macrophages (PS-M1/M2) also exhibited
cytokine profiles that were comparable to those generated from
primary monocytes (Figure 5B, Figure S5B).
Discussion
We have established a novel differentiation system for mono-
cytic cells from human ES and iPS cells. Since macrophages and
dendritic cells are usually obtained in vitro from monocytes, the
most important point of the evaluation is to establish whether
monocytes differentiated from ESCs/iPSCs are functionally
comparable to primary monocytes. In several functional assays,
PS-Mo indeed proved to be comparable to primary monocytes,
and importantly, PS-DCs and PC-MPs from PS-Mo were also
functionally comparable to their primary counterparts.
Although complete M1/M2 macrophage polarization still re-
quires aserum-containing medium, the present results prove that the
current method can precisely manipulate macrophages that have the
potential to differentiate into M1/M2 macrophages. The cytokine
profilesofPS-M1/M2werealsocomparable to thoseofprimaryM1/
M2 macrophages. The expression patterns of surface markers in PS-
DCs after LPS stimulation and of PS-MPs after M1/M2 polarization
were almost identical to those of DCs/MP derived from primary
monocytes. However, the level of IL-10 in PS-DCs after stimulation
was higher than that in primary DCs and the expression levels of
HLA-DR in PS-DCs/MP were low in comparison with those in
DCs/MP derived from primary monocytes. Therefore, further
improvement of culture conditions such as the use of a modified
medium and cytokine cocktail will be needed.
Several embryonic body methods and feeder cell co-culture
methods forPS-DCs/MPdifferentiationhavealreadybeenreported.
[7,27,29–30] These methods show relatively poor-reproducibility
because of the use of xenogeneic feeder cells and/or serum. In an
earlier reportwhichdescribesaprotocol thatcanderivemacrophages
and dendritic cells from human iPSCs in feeder- and serum-free
manner, [7] the authors did not fully characterize the monocytes and
noted that PS-DCs/MP were generated only from two of the five
iPSC clones tested. The current culture system simply propagated
progenitor cells in 2-dimensional cultures without passage or sorting,
and floating PS-Mo and PS-DCs/MP could be obtained repetitively
from all five ESC/iPSC clones tested (Figure S2 and S6). These
monocytic cells derived from disease- or patient- specific iPSC would
be useful tools for the examination of disease pathologies and for drug
discovery in immunological disorders such as autoimmune diseases,
immunodeficiencies and autoinflammatory syndromes. However,
even in our protocol, there are subtle clonal variations of timing of
differentiation such as the day of step 3 to 4 switching which is
determined bytheemergenceofCD43+CD45+cells (day13–15,data
not shown).Fineadjustmentof theprotocol foreachESC/iPSCclone
seemed to further improve the yield of monocytes.
iPSC technology is overcoming immunological and ethical
concerns in regenerative medicine using human pluripotent cells.
Furthermore, a number of disease-associated iPSCs generated
from patients with immunological disorders have been reported.
[15,31–34] Because patient- or disease-specific iPS cells will be an
important resource for unraveling human immunological dis-
orders, a robust and simple hematopoietic differentiation system
that can reliably mimic in vivo hematopoiesis is necessary for this
purpose. Our simple and robust protocol to produce monocytic
cells is therefore expected to be useful for regenerative medicine
and studies of immunological disorders.
Supporting Information
Figure S1 Image of floating hematopoietic cells derived
from iPS cells Phase contrast image of floating hemato-
poietic cells derived from iPS-201B7 at day 21 (step 4).
(PDF)
Figure S2 Phenotype analysis and gene expression
pattern of monocytic lineage cells derived from 3
additional pluripotent stem cell lines. (A) The percentage
of CD14+ cells within the total floating cells derived from 3 iPSC
clones (253G4, CIRA188Ai-W2, and CB-A11) was evaluated from
day 13 to day 28. (B) RT-PCR analysis of monocytic lineage cells
derived from 253G4, CIRA188Ai-W2, and CB-A11 clones for
expression of monocytic lineage marker genes (c-MAF, TLR4, and
CCL17). Peripheral blood monocytes and peripheral blood
monocyte-derived mature DCs were used as positive controls.
(PDF)
Figure S3 Characteristics of primary monocytes and
macrophages. (A) Phase contrast image and (B) flow cytometric
analysis of macrophages derived from primary monocytes. (C) The
levels of IL-6 and TNF-a in supernatants of primary monocyte
culture medium 4 hours after LPS stimulation. (D) The levels of
IL-1b were measured 4 hours after LPS stimulation with/without
an additional 30-minute ATP stimulation.
(PDF)
Figure S4 Characteristics and functional assays of
dendritic cells derived from primary monocytes. (A)
Flow cytometric analysis of immature/mature DCs derived from
primary monocytes. (B) The levels of IL-10 and TNF-a in
supernatants of culture medium with primary-DCs 24 hours after
LPS stimulation. (C) The proliferation of allogeneic naı¨ve T cells
(16105 cells per well) co-cultured with 40 Gy-irradiated stimulator
cells for 3 days was evaluated. The proliferation of naı¨ve T cells in
the last 16 hours was measured by 3H-thymidine uptake.
(PDF)
Figure S5 Characteristics and functional assays of M1/
M2 macrophages derived from primary monocytes. (A)
Flow cytometric analysis of M1/M2 macrophages derived from
primary monocytes. (B) The levels of IL-12p70 and IL-10 in
supernatants of culture medium with M1/M2 macrophages
derived from primary monocytes 24 hours after LPS stimulation.
(PDF)
Figure S6 Replication assays for 3 additional pluripo-
tent stem cell lines. (A) Phase contrast image (left) and May-
Giemsa staining (right) of mature DCs derived from iPSC clones.
(B) Phase contrast image of macrophages derived from iPSC
clones. (C) Flow cytometric analysis of immature/mature DCs and
macrophages derived from iPSC clones.
(PDF)
Table S1 Primers for RT-PCR.
(PDF)
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